Picture of Syros Pharmaceuticals logo

SYRS Syros Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Syros Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of 10 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -85 cents.  The mean expectation of
five analysts for the quarter was for a loss of 87 cents per
share. Wall Street expected results to range from $-1.20 to -69
cents per share.
    * Reported revenue was zero​; analysts expected $720.00
thousand. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 10 cents​.
    * The company reported a quarterly loss of $3.71 million.
    * Syros Pharmaceuticals Inc shares had fallen by 5.4% this
quarter and lost 35.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $14.00 
This summary was machine generated from LSEG data May 14 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.87          -0.10          Beat
 Dec. 31 2023      -1.14          -2.18          Missed
 Sep. 30 2023      -1.14          -1.43          Missed
 Jun. 30 2023      -1.13          -1.30          Missed

Recent news on Syros Pharmaceuticals

See all news